DKTK Core Facilities: PDX-Models

 

Characteristics of AML PDX samples that were established within the first DKTK funding period © AG Jeremias

Xenograft mouse model of acute leukemias


The Core Facility "PDX-Models" studies primary patients´ tumor cells growing in mice, performs preclinical treatment trials and molecular studies on basic disease biology.

In vivo bioluminescence imaging (BLI) allows reliable and sensitive follow-up of preclinical treatment trials © AG Jeremias

The core facility offers:

  • engrafting and amplifying primary tumor cells from patients with ALL or AML as patient-derived xenografts (PDX) in mice
  • biobank of re-transplantable PDX samples for in vitro studies, >50 for ALL and >10 for AML
  • genetic engineering in PDX (GEPDX) cells for overexpression of transgenes
  • preclinical in vivo treatment trials monitored by bioluminescence in vivo imaging
    • quantifying treatment responses as early as 4 days after treatment
    • covering all disease stages including minimal residual disease
    • focusing on challenging sub-populations such as dormant stem cells

More information on the Xenograft Facility München

Coordination

#
Prof. Dr. Irmela Jeremias

Dr. von Haunersches Kinderspital

Klinikum der Universität München Helmholtz Zentrum München

Marchioninistraße 25
81377 München
Send message